title: Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma--phase II study results.
abstract: In a phase II clinical study, pretreated multiple myeloma patients with relapsing or stable disease received autologous anticancer vaccine containing dendritic cells loaded with Id-protein. Patients received a total of 6 vaccine doses intradermally in monthly intervals. No clinical responses were observed. During the follow-up with a median of 33.1 months (range: 11-43 months), the disease remained stable in 7/11 (64%) of patients. Immune responses measured by ELISpot were noted in 3/11 (27%) and DTH skin test for Id-protein was positive in 8/11 (73%) of patients; out of those, 1/11 (9%) and 5/11 (46%), respectively, had preexisting immune response to Id-protein before the vaccination began. Outcomes were compared to those of a control group of 13 patients. A trend to lower cumulative incidence of progression in the vaccinated group was observed at 12 months from the first vaccination (p= 0.099). More patients from the control group compared to vaccinated patients required active anticancer therapy [4/11 (36%) vs. 8/13 (62%)]. Vaccines based on dendritic cells loaded with Id-protein are safe and induce specific immune response in multiple myeloma patients. Our results suggest that the vaccination could stabilize the disease in approximately two-thirds of patients.
  
  
  BACKGROUND
  dendritic cells, immunotherapy, anticancer vaccines, Id-protein, multiple myeloma.
authors.affiliation: Department of Internal Medicine-Hematooncology, University Hospital Brno and Masaryk University Brno, Jihlavska 20, 625 00, Brno, Czech Republic. lzahradova@fnbrno.cz
authors.forename: L
authors.initials: L
authors.lastname: Zahradova
authors.forename: K
authors.initials: K
authors.lastname: Mollova
authors.forename: D
authors.initials: D
authors.lastname: Ocadlikova
authors.forename: L
authors.initials: L
authors.lastname: Kovarova
authors.forename: Z
authors.initials: Z
authors.lastname: Adam
authors.forename: M
authors.initials: M
authors.lastname: Krejci
authors.forename: L
authors.initials: L
authors.lastname: Pour
authors.forename: A
authors.initials: A
authors.lastname: Krivanova
authors.forename: V
authors.initials: V
authors.lastname: Sandecka
authors.forename: R
authors.initials: R
authors.lastname: Hajek
mesh_terms: D000276:Adjuvants, Immunologic; D000368:Aged; D019496:Cancer Vaccines / Q000627:therapeutic use*; D016022:Case-Control Studies; D003713:Dendritic Cells / Q000276:immunology* / Q000637:transplantation; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006433:Hemocyanins / Q000276:immunology; D006801:Humans; D006968:Hypersensitivity, Delayed; D007167:Immunotherapy; D051796:Inhibitor of Differentiation Proteins / Q000276:immunology* / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000276:immunology / Q000628:therapy*; D009367:Neoplasm Staging; D011379:Prognosis; D015996:Survival Rate; D014611:Vaccination
chemical_list: D000276:Adjuvants, Immunologic; D019496:Cancer Vaccines; D051796:Inhibitor of Differentiation Proteins; D006433:Hemocyanins